Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.37 |
| ▸ | PDE6A | P16499 | 1/20 | 0.37 |
| ▸ | PDE6G | P18545 | 1/20 | 0.37 |
| ▸ | PDE6B | P35913 | 1/20 | 0.37 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207024 | 0.80 | LMNA (0.52) | AKR1B1KMT2AMEN1TSHRLMNA | |
| SCHEMBL6229563 | 0.76 | AKR1B1 (0.47) | AKR1B1KMT2ALMNAMAPTGAA | |
| SCHEMBL6206245 | 0.76 | AKR1B1 (0.53) | AKR1B1KMT2AMEN1TSHRLMNA | |
| SCHEMBL6206811 | 0.74 | AKR1B1 (0.50) | AKR1B1KMT2ALMNAMAPTCNR2 | |
| SCHEMBL13290771 | 0.71 | AKR1B1 (0.44) | AKR1B1TP53KMT2AMEN1TSHR | |
| SCHEMBL6205922 | 0.70 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL4448833 | 0.69 | AKR1B1 (0.61) | AKR1B1KMT2AMEN1LMNAMAPT | |
| SCHEMBL6206633 | 0.69 | MAPT (0.54) | AKR1B1KMT2AMEN1LMNAMAPT | |
| SCHEMBL25248250 | 0.68 | NNMT (0.41) | LMNAMAPTKDM4E | |
| SCHEMBL4450397 | 0.68 | NNMT (0.41) | TP53LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6872722-B2 | Therapies for tissue damage resulting from ischemia | PFIZER INC (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1260224-B1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | PFIZER PROD INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | MYLARI BANAVARA L (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1260224-A1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | AKR1B1 2/4885TP53 4269/4885KMT2A 4265/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | AKR1B1 3/4885TP53 4206/4885KMT2A 4276/4885 |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | TNNI3, TNNC1, TNNT2 | AKR1B1 2046/4885TP53 1690/4885KMT2A 4671/4885 |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | AKR1B1 3/4885TP53 4132/4885KMT2A 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.